LT3247707T - 4-metilsulfonilu pakeistieji piperidino karbamido junginiai, naudotini širdies sutrikimų, tokių kaip dilatacinė kardiomiopatija (dcm), gydymui - Google Patents
4-metilsulfonilu pakeistieji piperidino karbamido junginiai, naudotini širdies sutrikimų, tokių kaip dilatacinė kardiomiopatija (dcm), gydymuiInfo
- Publication number
- LT3247707T LT3247707T LTEPPCT/US2016/014365T LT16014365T LT3247707T LT 3247707 T LT3247707 T LT 3247707T LT 16014365 T LT16014365 T LT 16014365T LT 3247707 T LT3247707 T LT 3247707T
- Authority
- LT
- Lithuania
- Prior art keywords
- methylsulfonyl
- dcm
- treatment
- compounds useful
- dilated cardiomyopathy
- Prior art date
Links
- -1 4-methylsulfonyl-substituted piperidine urea compounds Chemical class 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 title 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 title 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106571P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014365 WO2016118774A1 (en) | 2015-01-22 | 2016-01-21 | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3247707T true LT3247707T (lt) | 2023-08-25 |
Family
ID=55275230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/014365T LT3247707T (lt) | 2015-01-22 | 2016-01-21 | 4-metilsulfonilu pakeistieji piperidino karbamido junginiai, naudotini širdies sutrikimų, tokių kaip dilatacinė kardiomiopatija (dcm), gydymui |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9925177B2 (es) |
| EP (2) | EP4234017A3 (es) |
| JP (1) | JP6712275B2 (es) |
| KR (2) | KR20230145504A (es) |
| CN (3) | CN118164961A (es) |
| AU (3) | AU2016209200B2 (es) |
| BR (1) | BR112017015627B1 (es) |
| CA (1) | CA2974370C (es) |
| CL (1) | CL2017001871A1 (es) |
| CO (1) | CO2017008398A2 (es) |
| CR (1) | CR20170370A (es) |
| DK (1) | DK3247707T3 (es) |
| DO (2) | DOP2017000166A (es) |
| EA (1) | EA036923B1 (es) |
| EC (1) | ECSP17054181A (es) |
| ES (1) | ES2953480T3 (es) |
| FI (1) | FI3247707T3 (es) |
| GT (1) | GT201700163A (es) |
| HK (1) | HK1246775A1 (es) |
| HR (1) | HRP20230737T1 (es) |
| HU (1) | HUE063410T2 (es) |
| IL (5) | IL295547A (es) |
| LT (1) | LT3247707T (es) |
| MX (3) | MX2017009540A (es) |
| PE (2) | PE20171511A1 (es) |
| PH (1) | PH12017501279A1 (es) |
| PL (1) | PL3247707T3 (es) |
| PT (1) | PT3247707T (es) |
| RS (1) | RS64432B1 (es) |
| SG (2) | SG10201913047UA (es) |
| SI (1) | SI3247707T1 (es) |
| TN (1) | TN2017000320A1 (es) |
| UA (1) | UA119905C2 (es) |
| WO (1) | WO2016118774A1 (es) |
| ZA (1) | ZA201704777B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| AR112804A1 (es) | 2017-09-13 | 2019-12-11 | Amgen Inc | Compuestos de bisamida que activan el sarcómero y sus usos |
| MX2020007532A (es) | 2018-01-19 | 2020-09-09 | Cytokinetics Inc | Inhibidores de sarcomero cardiaco. |
| JP7402804B2 (ja) * | 2018-02-01 | 2023-12-21 | マイオカーディア，インク | ピラゾール化合物及びその調製 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| BR112021003496A2 (pt) | 2018-08-31 | 2021-05-18 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco |
| GB201905520D0 (en) | 2019-04-18 | 2019-06-05 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| SG11202112723PA (en) * | 2019-05-19 | 2021-12-30 | Myokardia Inc | Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide |
| CN114127061A (zh) | 2019-07-16 | 2022-03-01 | 迈奥卡迪亚公司 | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| EP4164644A1 (en) * | 2020-06-15 | 2023-04-19 | MyoKardia, Inc. | Treatment of atrial dysfunction |
| KR102541297B1 (ko) | 2020-08-18 | 2023-06-09 | 가톨릭대학교 산학협력단 | 확장성 심근병 모델 및 이의 제조방법 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| CN116082326A (zh) * | 2022-12-16 | 2023-05-09 | 药康众拓(江苏)医药科技有限公司北京分公司 | 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250789A1 (en) * | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| TWI359812B (en) * | 2004-06-17 | 2012-03-11 | Cytokinetics Inc | Compounds, compositions and methods |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| US8324178B2 (en) * | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2011059021A1 (ja) * | 2009-11-11 | 2011-05-19 | 大日本住友製薬株式会社 | ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体 |
-
2016
- 2016-01-21 UA UAA201708527A patent/UA119905C2/uk unknown
- 2016-01-21 PE PE2017001241A patent/PE20171511A1/es unknown
- 2016-01-21 IL IL295547A patent/IL295547A/en unknown
- 2016-01-21 PT PT167026525T patent/PT3247707T/pt unknown
- 2016-01-21 ES ES16702652T patent/ES2953480T3/es active Active
- 2016-01-21 PE PE2021001384A patent/PE20212253A1/es unknown
- 2016-01-21 CN CN202410163448.9A patent/CN118164961A/zh active Pending
- 2016-01-21 DK DK16702652.5T patent/DK3247707T3/da active
- 2016-01-21 MX MX2017009540A patent/MX2017009540A/es unknown
- 2016-01-21 LT LTEPPCT/US2016/014365T patent/LT3247707T/lt unknown
- 2016-01-21 JP JP2017538593A patent/JP6712275B2/ja active Active
- 2016-01-21 CA CA2974370A patent/CA2974370C/en active Active
- 2016-01-21 SI SI201631723T patent/SI3247707T1/sl unknown
- 2016-01-21 EA EA201791656A patent/EA036923B1/ru not_active IP Right Cessation
- 2016-01-21 PL PL16702652.5T patent/PL3247707T3/pl unknown
- 2016-01-21 KR KR1020237033324A patent/KR20230145504A/ko active IP Right Grant
- 2016-01-21 KR KR1020177022900A patent/KR102585550B1/ko active IP Right Grant
- 2016-01-21 RS RS20230542A patent/RS64432B1/sr unknown
- 2016-01-21 EP EP23170487.5A patent/EP4234017A3/en active Pending
- 2016-01-21 SG SG10201913047UA patent/SG10201913047UA/en unknown
- 2016-01-21 FI FIEP16702652.5T patent/FI3247707T3/fi active
- 2016-01-21 BR BR112017015627-0A patent/BR112017015627B1/pt active IP Right Grant
- 2016-01-21 SG SG11201705928XA patent/SG11201705928XA/en unknown
- 2016-01-21 MX MX2022007040A patent/MX2022007040A/es unknown
- 2016-01-21 HR HRP20230737TT patent/HRP20230737T1/hr unknown
- 2016-01-21 AU AU2016209200A patent/AU2016209200B2/en active Active
- 2016-01-21 HU HUE16702652A patent/HUE063410T2/hu unknown
- 2016-01-21 MX MX2021010778A patent/MX2021010778A/es unknown
- 2016-01-21 US US15/003,662 patent/US9925177B2/en active Active
- 2016-01-21 CR CR20170370A patent/CR20170370A/es unknown
- 2016-01-21 CN CN201680017126.7A patent/CN107428719B/zh active Active
- 2016-01-21 CN CN202010152637.8A patent/CN111393414B/zh active Active
- 2016-01-21 EP EP16702652.5A patent/EP3247707B1/en active Active
- 2016-01-21 WO PCT/US2016/014365 patent/WO2016118774A1/en active Application Filing
- 2016-01-21 TN TNP/2017/000320A patent/TN2017000320A1/en unknown
-
2017
- 2017-07-13 PH PH12017501279A patent/PH12017501279A1/en unknown
- 2017-07-14 ZA ZA2017/04777A patent/ZA201704777B/en unknown
- 2017-07-18 IL IL253552A patent/IL253552B/en active IP Right Grant
- 2017-07-19 DO DO2017000166A patent/DOP2017000166A/es unknown
- 2017-07-20 GT GT201700163A patent/GT201700163A/es unknown
- 2017-07-20 CL CL2017001871A patent/CL2017001871A1/es unknown
- 2017-08-17 CO CONC2017/0008398A patent/CO2017008398A2/es unknown
- 2017-08-21 EC ECIEPI201754181A patent/ECSP17054181A/es unknown
-
2018
- 2018-05-09 HK HK18105987.4A patent/HK1246775A1/zh unknown
-
2019
- 2019-11-28 IL IL271034A patent/IL271034A/en active IP Right Grant
-
2020
- 2020-09-30 AU AU2020244490A patent/AU2020244490B2/en active Active
- 2020-12-06 IL IL279247A patent/IL279247A/en unknown
-
2021
- 2021-09-13 IL IL286369A patent/IL286369A/en unknown
-
2022
- 2022-08-24 DO DO2022000172A patent/DOP2022000172A/es unknown
-
2023
- 2023-01-24 AU AU2023200361A patent/AU2023200361A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286369A (en) | Piperidine-4-methylsulfonyl-modified urea compounds for the treatment of dilated cardiomyopathy (dcm) | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| HRP20181772T1 (hr) | Spoj za obradu gnojiva koje sadrži ureu | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| HK1258964A1 (zh) | 用於製備1，3-苯並間二氧雜環戊烯雜環化合物的方法 | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL249640A0 (en) | Preparations for the treatment of nosebleeds | |
| IL268835B (en) | A process for the preparation of 2-cyanoimidazole compounds | |
| IL275480A (en) | A process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| HRP20181123T1 (hr) | Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac | |
| GB201402287D0 (en) | Novel cyclic amine compounds and improved treatment for cardiac and cardiovascular disease |